Moderna's Cancer Vaccine Faces a Harder Question Than Keytruda

Moderna's first Phase 3 data for a cancer vaccine has raised a question the company may not have expected: whether the treatment is needed at all. The early results have added weight to a debate that goes beyond a single trial readout.

The obvious comparison is with Merck's Keytruda, the immunotherapy that Moderna's vaccine is being tested alongside. But the more important test is not whether the vaccine can outperform that drug in a snapshot. For patients who have already had a tumor removed, the real goal is keeping the disease from coming back, and that takes years of follow-up to measure.

That distinction matters for how the data should be read. Early response figures can look encouraging while revealing little about recurrence, which is the outcome that will decide whether a vaccine earns a place in treatment plans. Doctors, regulators and payers will want to see durable benefit, not just a promising first look.

For Moderna, the stakes are significant. The company built its reputation on mRNA technology during the COVID-19 pandemic and has been working to extend that platform into oncology. A clear answer on long-term protection against recurrence would do more to justify that bet than any early comparison. Until then, the open question is whether the benefit lasts.